• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, October 4, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

New medication significantly decreases involuntary movement

Bioengineer by Bioengineer
April 7, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: University of South Florida

Tampa, FL (April 7, 2017) Antipsychotic treatment can cause involuntary movements such as lip smacking, tongue protrusions and excessive eye blinking. These movements typically occur after more than 3 months of treatment and are called tardive dyskinesia.

Robert A. Hauser, MD, MBA, professor of neurology at the University of South Florida in Tampa, is the lead author of a study published in the American Journal of Psychiatry that concludes valbenazine administered once daily can significantly reduce tardive dyskinesia in patients with schizophrenia, schizoaffective disorder and mood disorder.

"One approach to managing tardive dyskinesia is to discontinue antipsychotic treatment or reduce the dosage, but these options are not always feasible, because withdrawal can exacerbate tardive dyskinesia symptoms or have a negative impact on psychiatric status. Moreover, tardive dyskinesia symptoms often persist even after discontinuation or dosage reduction," wrote Dr. Hauser, who directs the Parkinson's Disease and Movement Disorders Center at USF.

Valbenazine is a selective vesicular monoamine transporter 2 inhibitor. Two hundred twenty-five people with schizophrenia, schizoaffective disorder or a mood disorder participated in the phase 3 randomized double blind, placebo-controlled trial.

Forty-percent of those who received valbenazine 80mg/day improved by at least 50 percent. That's compared to just 8 percent in the placebo group.

Researchers also determined that valbenazine was well tolerated. Drowsiness, restlessness and dry mouth were reported as adverse effects.

###

Media Contact

Tina Meketa
[email protected]
813-955-2593

http://www.hsc.usf.edu

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Plant Compound Salvianolic Acid B Shields Heart Cells From Sugar-Driven Inflammatory Cell Death

Plant Compound Salvianolic Acid B Shields Heart Cells From Sugar-Driven Inflammatory Cell Death

October 4, 2026
Hidden Disorder Flips Magnetism in a Double Perovskite Crystal

Hidden Disorder Flips Magnetism in a Double Perovskite Crystal

October 4, 2026

Scientists Find Druggable Switch That Controls the Cell’s Master Recycling Regulator TFEB

October 4, 2026

MUC1: The Sticky Protein That Turns Guardian of Epithelia Into Engine of Cancer

October 4, 2026
Please login to join discussion

POPULAR NEWS

  • Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

    Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

    29 shares
    Share 12 Tweet 7
  • Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes

    29 shares
    Share 12 Tweet 7
  • Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells

    29 shares
    Share 12 Tweet 7
  • New Scale Measures How Ready Nurse Educators Really Are for the AI Era

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes

Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.